MediciNova Inc (MNOV) - Total Assets
Based on the latest financial reports, MediciNova Inc (MNOV) holds total assets worth $47.58 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check MNOV capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
MediciNova Inc - Total Assets Trend (2001–2024)
This chart illustrates how MediciNova Inc's total assets have evolved over time, based on quarterly financial data. Explore MNOV long-term investments to assets to see how much of total assets are deployed in long-term investments.
MediciNova Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
MediciNova Inc's total assets of $47.58 Million consist of 73.5% current assets and 26.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.80 Million | 8.6% |
| Goodwill | $9.60 Million | 17.2% |
Asset Composition Trend (2001–2024)
This chart illustrates how MediciNova Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MediciNova Inc (MNOV) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MediciNova Inc's current assets represent 73.5% of total assets in 2024, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 72.2% of total assets in 2024, up from 0.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 17.2% of total assets.
MediciNova Inc Competitors by Total Assets
Key competitors of MediciNova Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
MediciNova Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.86 | 16.66 | 27.67 |
| Quick Ratio | 9.86 | 16.66 | 27.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $29.59 Million | $40.67 Million | $58.52 Million |
MediciNova Inc - Advanced Valuation Insights
This section examines the relationship between MediciNova Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.79 |
| Latest Market Cap to Assets Ratio | 1.18 |
| Asset Growth Rate (YoY) | -15.7% |
| Total Assets | $55.88 Million |
| Market Capitalization | $65.86 Million USD |
Valuation Analysis
Above Book Valuation: The market values MediciNova Inc's assets above their book value (1.18x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: MediciNova Inc's assets decreased by 15.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for MediciNova Inc (2001–2024)
The table below shows the annual total assets of MediciNova Inc from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $55.88 Million | -15.68% |
| 2023-12-31 | $66.27 Million | -10.63% |
| 2022-12-31 | $74.15 Million | -15.16% |
| 2021-12-31 | $87.41 Million | +15.89% |
| 2020-12-31 | $75.42 Million | -4.78% |
| 2019-12-31 | $79.21 Million | +2.57% |
| 2018-12-31 | $77.22 Million | +77.85% |
| 2017-12-31 | $43.42 Million | +9.06% |
| 2016-12-31 | $39.81 Million | +5.03% |
| 2015-12-31 | $37.91 Million | +38.99% |
| 2014-12-31 | $27.27 Million | -7.69% |
| 2013-12-31 | $29.55 Million | +50.99% |
| 2012-12-31 | $19.57 Million | -36.44% |
| 2011-12-31 | $30.79 Million | -57.79% |
| 2010-12-31 | $72.93 Million | -22.68% |
| 2009-12-31 | $94.33 Million | +87.81% |
| 2008-12-31 | $50.22 Million | -31.90% |
| 2007-12-31 | $73.75 Million | -33.91% |
| 2006-12-31 | $111.59 Million | -21.63% |
| 2005-12-31 | $142.39 Million | +164.83% |
| 2004-12-31 | $53.77 Million | +854.82% |
| 2003-12-31 | $5.63 Million | +255.06% |
| 2002-12-31 | $1.59 Million | -81.07% |
| 2001-12-31 | $8.38 Million | -- |
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis… Read more